Susquehanna International Group, LLP Clene Inc. Call Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	SELL	$0.28 - $0.53 $3,640 - $6,890	-13,000 Reduced 21.81%	46,600 $20,000
Q4 2023 Feb 14, 2024	SELL	$0.26 - $0.55 $14,326 - $30,305	-55,100 Reduced 48.04%	59,600 $17,000
Q3 2023 Nov 14, 2023	BUY	$0.46 - $0.87 $34,362 - $64,989	74,700 Added 186.75%	114,700 $57,000
Q2 2023 Aug 11, 2023	BUY	$0.78 - $1.22 $11,076 - $17,324	14,200 Added 55.04%	40,000 $35,000
Q1 2023 May 16, 2023	SELL	$0.95 - $1.62 $5,130 - $8,748	-5,400 Reduced 17.31%	25,800 $29,000

Q4 2022 Feb 14, 2023	SELL	$0.92 - $1.11 $496,800 - $599,400	-540,000 Reduced 94.54%	31,200 $31,000
Q3 2022 Nov 14, 2022	BUY	$0.33 - $4.83 $173,349 - $2.54 Million	525,300 Added 1144.44%	571,200 $1.6 Million
Q2 2022 Aug 15, 2022	SELL	$2.1 - $4.12 $171,780 - $337,016	-81,800 Reduced 64.06%	45,900 $116,000
Q1 2022 May 16, 2022	SELL	$2.42 - $4.42 $54,208 - $99,008	-22,400 Reduced 14.92%	127,700 $503,000
Q4 2021 Feb 14, 2022	BUY	$3.95 - $7.53 $63,595 - $121,233	16,100 Added 12.01%	150,100 $615,000
Q3 2021 Nov 15, 2021	BUY	$6.83 - $13.58 $915,220 - $1.82 Million	134,000 New	134,000 $915,000

7.44M

48.1K

160K

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $21M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.